Lophius Biosciences Appoints Dr Robert Phelps as director of business operations
German biotechnology company Lophius Biosciences GmbH has announced that Dr Robert Phelps has joined the company as Director of Business Operations.
Dr. Phelps has more than 13 years of international experience in business development and licensing in the biotech and pharma industry. His last position was Head of Business Development & Licensing at SuppreMol GmbH in Munich, where he was responsible for all business development and licensing activities relating to the company’s clinical drug development candidates.
Lophius Biosciences is a privately held biotech company, focused on the development and marketing of diagnostic kits in the field of infectious and autoimmune diseases.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze